{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:31Z","timestamp":1772119291154,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple Myeloma (MM) is a hematological disease predominantly affecting elderly patients. The complexity of current treatment necessitates individualized approaches. Therein, functional assessment (FA) tools, such as the Revised Comorbidity Index (R-MCI) at our University- and Comprehensive Cancer Center Freiburg, play a crucial role. This study aimed to determine (a) the implementation of the R-MCI in our MM-tumor board (MM-TB), (b) its impact on treatment guidance at baseline and (c) potential changes during follow-up. This exploratory study investigated R-MCI coverage and distribution in a cohort of patients with multiple TB presentations. Among them, a follow-up patient cohort undergoing subsequent MM-therapy was analyzed to determine treatment adjustments and changes in patients\u2019 condition measured by R-MCI alterations. During our 3-year assessment period, 565 patients were presented in our MM-TB, totaling 1256\u00a0TB-presentations. In the multiple TB presentation cohort, the median number of TB presentations was 3 (range: 2\u201312). R-MCI scores within the MM-TB were available in 94%, whereas in 6%, the R-MCI had not been integrated. Among these, potential failure to identify the need for treatment modifications was determined. In the follow-up cohort, patient characteristics were typical for referral\/university centers. Dose reductions were performed in 55% and were more prevalent among patients with \u2265\u20094 vs. lesser TB presentations. Most patients (55%) showed a fitness stabilization or improvement via follow-up R-MCI. R-MCI integration in MM-TB exceeded\u2009&gt;\u200990%, indicating its successful integration for treatment support. Our results underscore its value in guiding therapy decisions, providing a comprehensive assessment beyond age considerations.<\/jats:p>","DOI":"10.1007\/s00277-024-06010-5","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T07:01:29Z","timestamp":1726902089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor board"],"prefix":"10.1007","author":[{"given":"Esther","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"R\u00e4der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Holler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Herget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"issue":"4","key":"6010_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1056\/NEJMe2314067","volume":"390","author":"EA Stadtmauer","year":"2024","unstructured":"Stadtmauer EA (2024) Antibody-based therapy for transplantation-eligible patients with multiple myeloma. N Engl J Med 390(4):368\u2013369","journal-title":"N Engl J Med"},{"issue":"4","key":"6010_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M et al (2024) Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med 390(4):301\u2013313","journal-title":"N Engl J Med"},{"issue":"10","key":"6010_CR3","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J et al (2023) Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 10(10):e825\u2013e837","journal-title":"Lancet Haematol"},{"issue":"2","key":"6010_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA et al (2022) Triplet Therapy, Transplantation, and maintenance until Progression in Myeloma. N Engl J Med 387(2):132\u2013147","journal-title":"N Engl J Med"},{"issue":"7","key":"6010_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","volume":"37","author":"EM Ocio","year":"2023","unstructured":"Ocio EM, Perrot A, Bories P et al (2023) Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation. Leukemia 37(7):1521\u20131529","journal-title":"Leukemia"},{"issue":"10","key":"6010_CR6","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.3390\/cancers15102693","volume":"15","author":"A Larocca","year":"2023","unstructured":"Larocca A, Cani L, Bertuglia G, Bruno B, Bringhen S (2023) New strategies for the treatment of older Myeloma patients. Cancers 15(10):2693","journal-title":"Cancers"},{"issue":"5","key":"6010_CR7","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Domm A-S, Dold SM et al (2017) A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102(5):910\u2013921","journal-title":"Haematologica"},{"issue":"3","key":"6010_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00277-022-05051-y","volume":"102","author":"B Frank","year":"2023","unstructured":"Frank B, Ihorst G, Herget G et al (2023) Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers. Ann Hematol 102(3):603\u2013611","journal-title":"Ann Hematol"},{"issue":"4","key":"6010_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3324\/haematol.2022.281489","volume":"108","author":"M Holler","year":"2023","unstructured":"Holler M, Ihorst G, Reinhardt H et al (2023) An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence. Haematologica 108(4):1115\u20131126","journal-title":"Haematologica"},{"issue":"1","key":"6010_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian H, McCurdy A, Giri S et al (2023) The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Blood Cancer J 13(1):6","journal-title":"Blood Cancer J"},{"issue":"8","key":"6010_CR11","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","volume":"32","author":"A Larocca","year":"2018","unstructured":"Larocca A, Dold SM, Zweegman S et al (2018) Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia 32(8):1697\u20131712","journal-title":"Leukemia"},{"issue":"18","key":"6010_CR12","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1002\/cncr.33658","volume":"127","author":"S Scheubeck","year":"2021","unstructured":"Scheubeck S, Ihorst G, Schoeller K et al (2021) Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. Cancer 127(18):3422\u20133436","journal-title":"Cancer"},{"issue":"4","key":"6010_CR13","first-page":"1279","volume":"109","author":"K Schoeller","year":"2024","unstructured":"Schoeller K, Ihorst G, Reinhardt H et al (2024) Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications. Haematologica 109(4):1279\u20131284","journal-title":"Haematologica"},{"issue":"6","key":"6010_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra2301292","volume":"391","author":"DH Kim","year":"2024","unstructured":"Kim DH, Rockwood K (2024) Frailty in older adults. N Engl J Med 391(6):538\u2013548","journal-title":"N Engl J Med"},{"issue":"10314","key":"6010_CR15","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H et al (2021) Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet Lond Engl 398(10314):1894\u20131904","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"6010_CR16","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1016\/S2666-7568(22)00169-6","volume":"3","author":"WK Soo","year":"2022","unstructured":"Soo WK, King MT, Pope A et al (2022) Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial. Lancet Healthy Longev 3(9):e617\u2013e627","journal-title":"Lancet Healthy Longev"},{"issue":"9","key":"6010_CR17","first-page":"e51","volume":"142","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Selder R, Pandurevic M et al (2017) [Multidisciplinary tumor boards: facts and satisfaction analysis of an indispensable Comprehensive Cancer Center Instrument]. Dtsch Med Wochenschr 1946 142(9):e51\u2013e60","journal-title":"Dtsch Med Wochenschr 1946"},{"key":"6010_CR18","unstructured":"Engelhardt M, Dold SM, Ihorst G, Knaus J, Schumacher M (2015) R-MCI webpage"},{"issue":"1","key":"6010_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12885-021-07878-6","volume":"21","author":"M Engelhardt","year":"2021","unstructured":"Engelhardt M, Ihorst G, Schumacher M et al (2021) Multidisciplinary tumor boards and their analyses: the Yin and Yang of outcome measures. BMC Cancer 21(1):173","journal-title":"BMC Cancer"},{"issue":"6","key":"6010_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"M-V Mateos","year":"2018","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M et al (2018) Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma. N Engl J Med 378(6):518\u2013528","journal-title":"N Engl J Med"},{"issue":"2","key":"6010_CR21","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","volume":"21","author":"M Engelhardt","year":"2021","unstructured":"Engelhardt M, Ihorst G, Singh M et al (2021) Real-world evaluation of Health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk 21(2):e160\u2013e175","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"6010_CR22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/jgs.15715","volume":"67","author":"TM Wildes","year":"2019","unstructured":"Wildes TM, Tuchman SA, Klepin HD et al (2019) Geriatric assessment in older adults with multiple myeloma. J Am Geriatr Soc 67(5):987\u2013991","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"6010_CR23","first-page":"215","volume":"8","author":"H Mian","year":"2019","unstructured":"Mian H, Brouwers M, Kouroukis CT, Wildes TM (2019) Comparison of Frailty scores in newly diagnosed patients with multiple myeloma: a review. J Frailty Aging 8(4):215\u2013221","journal-title":"J Frailty Aging"},{"issue":"8","key":"6010_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/oncolo\/oyac079","volume":"27","author":"CE Jensen","year":"2022","unstructured":"Jensen CE, Vohra SN, Nyrop KA et al (2022) Physical function, Psychosocial Status, and Symptom Burden among adults with plasma cell disorders and associations with Quality of Life. Oncologist 27(8):694\u2013702","journal-title":"Oncologist"},{"key":"6010_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejim.2018.02.001","volume":"58","author":"B Eichhorst","year":"2018","unstructured":"Eichhorst B, Hallek M, Goede V (2018) Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med 58:7\u201313","journal-title":"Eur J Intern Med"},{"issue":"5","key":"6010_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman S, Engelhardt M, Larocca A (2017) EHA SWG on \u2018Aging and hematology.\u2019 Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol 29(5):315\u2013321","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"6010_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3324\/haematol.2018.200881","volume":"104","author":"C Greil","year":"2019","unstructured":"Greil C, Engelhardt M, Ihorst G et al (2019) Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica 104(2):370\u2013379","journal-title":"Haematologica"},{"issue":"1","key":"6010_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12885-020-06809-1","volume":"20","author":"M Freytag","year":"2020","unstructured":"Freytag M, Herrlinger U, Hauser S et al (2020) Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer 20(1):355","journal-title":"BMC Cancer"},{"issue":"9","key":"6010_CR29","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1016\/S2666-7568(22)00172-6","volume":"3","author":"F Efficace","year":"2022","unstructured":"Efficace F, Gaidano G, Petrucci MT et al (2022) Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study. Lancet Healthy Longev 3(9):e628\u2013e635","journal-title":"Lancet Healthy Longev"},{"key":"6010_CR30","doi-asserted-by":"crossref","unstructured":"Patel BG, Luo S, Wildes TM, Sanfilippo KM (2020) Frailty in older adults with multiple myeloma: a study of US veterans. JCO Clin Cancer Inf ;(4):117\u2013127","DOI":"10.1200\/CCI.19.00094"},{"issue":"1","key":"6010_CR31","doi-asserted-by":"publisher","first-page":"101401","DOI":"10.1016\/j.jgo.2022.10.016","volume":"14","author":"J De La Rubia","year":"2023","unstructured":"De La Rubia J, Gonz\u00e1lez B, Cruz-Jentoft AJ et al (2023) Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: the RETROGAH study. J Geriatr Oncol 14(1):101401","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"6010_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jgo.2018.05.015","volume":"10","author":"AE Rosko","year":"2019","unstructured":"Rosko AE, Huang Y, Benson DM et al (2019) Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. J Geriatr Oncol 10(3):479\u2013485","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"6010_CR33","doi-asserted-by":"publisher","first-page":"101680","DOI":"10.1016\/j.jgo.2023.101680","volume":"15","author":"CE Jensen","year":"2024","unstructured":"Jensen CE, Deal AM, Nyrop KA et al (2024) Geriatric assessment-guided interventions for older adults with multiple myeloma: a feasibility and acceptability study. J Geriatr Oncol 15(2):101680","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"6010_CR34","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.3324\/haematol.2018.189969","volume":"103","author":"JM Waldschmidt","year":"2018","unstructured":"Waldschmidt JM, Keller A, Ihorst G et al (2018) Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I\/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). Haematologica 103(10):e473\u2013e479","journal-title":"Haematologica"},{"issue":"1","key":"6010_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N et al (2020) A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 34(1):224\u2013233","journal-title":"Leukemia"},{"issue":"4","key":"6010_CR36","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ et al (2022) Daratumumab plus Lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia 36(4):1066\u20131077","journal-title":"Leukemia"},{"issue":"22","key":"6010_CR37","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1182\/blood.2020009507","volume":"137","author":"A Larocca","year":"2021","unstructured":"Larocca A, Bonello F, Gaidano G et al (2021) Dose\/schedule-adjusted Rd-R vs continuous rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 137(22):3027\u20133036","journal-title":"Blood"},{"key":"6010_CR38","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/EDBK_239067","volume":"39","author":"R Mina","year":"2019","unstructured":"Mina R, Bringhen S, Wildes TM, Zweegman S, Rosko AE (2019) Approach to the older adult with multiple myeloma. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 39:500\u2013518","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"6010_CR39","unstructured":"Coulson AB, Royle K-L, Pawlyn C et al (2022) Protocol: Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open. ;12(6)"},{"issue":"24","key":"6010_CR40","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","volume":"26","author":"JR Anderson","year":"2008","unstructured":"Anderson JR, Cain KC, Gelber RD (2008) Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol off J Am Soc Clin Oncol 26(24):3913\u20133915","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"3","key":"6010_CR41","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3324\/haematol.2020.254235","volume":"106","author":"SM Dold","year":"2021","unstructured":"Dold SM, M\u00f6ller M-D, Ihorst G et al (2021) Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica 106(3):875\u2013880","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06010-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06010-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06010-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T07:02:36Z","timestamp":1726902156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06010-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":41,"alternative-id":["6010"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06010-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4432469\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"(EV EK 22-1491-S1)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}